Financial Post EN

Spectral Medical and Vantive Announce Publication of Complete Results from Spectral’s Tigris Trial in the Lancet Respiratory Medicine

Tigris publication confirms positive results for primary and key secondary endpoints with 95.3% and 99.4% probability of benefit for PMX at 28-day and 90-day mortality After adjusting for baseline severity, absolute risk reduction for mortality of 10.3% at 28-days and 15.5% at 90-days Safety profile consistent with standard of care with no significant difference in […]

Mar 24, 2026 &03062424202631; 11:06 UTC financialpost.com Trending 3/5

Read original on financialpost.com ↗

→

Neutral impact

Sentiment score: +15/100

Low impact Medium-term (weeks)

WHAT THIS MEANS

Spectral Medical's Tigris trial results published in Lancet Respiratory Medicine show positive efficacy for PMX treatment in sepsis with strong mortality reduction claims (10.3% at 28-day, 15.5% at 90-day). However, the news is 329 minutes old and likely already absorbed by the market.

AI CONFIDENCE

35% Low

SENTIMENT GAUGE

NEWS POWER SCORE

AFFECTED ASSETS

⇅

SPEC.TO

SPEC.TOStock

High volatility expected

Positive clinical trial results are constructive long-term, but 5.5+ hour delay means institutional investors have already positioned. Micro-cap biotech volatility dominates short-term price action regardless of news age.

PRICE HISTORY

Loading chart...

⚡ SUGGESTED ACTION

SKIP THIS TRADE. The publication is positive for long-term thesis but the 329-minute delay eliminates intraday tradability. If holding SPEC.TO, this validates thesis; if not, entry point has passed. Monitor for institutional accumulation over weeks, not hours. [PRICED_IN] [MOVE:0.3%]

KEY SIGNALS

News is stale (>5 hours old) — market reaction window closedClinical trial positive but not unexpected (Tigris was known trial)No real-time market data provided for Spectral Medical stock itselfBroad market flat (S&P 500 +0%, VIX stable) — no sector rotation signal

SECTORS INVOLVED

HealthcareBiotechnology

Analysis generated on Mar 24, 2026 at 16:35 UTC

Disclaimer: This analysis is generated by artificial intelligence for informational purposes only and does not constitute financial advice, investment recommendation, or solicitation. Original reporting by Financial Post. Always conduct your own research and consult a qualified financial advisor before making investment decisions.

Spectral Medical and Vantive Announce Publication of Complete Results from Spectral’s Tigris Trial in the Lancet Respiratory Medicine

RELATED INTELLIGENCE